Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Drugs Aging ; 41(2): 125-139, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37880500

ABSTRACT

BACKGROUND: Hip fracture (HF) mostly affects older adults and is responsible for increased morbidity and mortality. Non-steroidal anti-inflammatory drugs (NSAIDs) are part of the peri-operative multimodal analgesic management, but their use could be associated with adverse events in older adults. This systematic review aimed to assess outcomes associated with NSAIDs use in the peri-operative period of HF surgery. METHODS: This systematic review was conducted according to the PRISMA guidelines. Three databases (PubMed/EMBASE/Cochrane Central) were used to search for clinical trials and observational studies assessing efficacy, safety and impact of NSAIDs use on non-specific post-operative outcomes, such as functional status and post-operative complications. RESULTS: Among the 1320 references initially identified, four provided data on efficacy, four on safety and six on non-specific post-operative outcomes (three randomized controlled clinical trials, three observational studies). Mean study population ages ranged from 68 to 87 years. Two studies found that NSAIDs were effective on pain control, but two studies found conflicting results on opioid sparing. No increased risk of acute kidney injury was observed, while results concerning bleeding risk and delirium were conflicting. No study has found any effect of NSAIDs use on walk recovery. Quality of evidence was high for pain control, but low to very low for all the other studied outcomes. CONCLUSIONS: The use of NSAIDs may be effective for pain control in the peri-operative period of HF surgery. However, safety data were conflicting with low levels of certainty. Further studies are needed to assess their benefit-risk balance in this context. The research protocol was previously registered on PROSPERO (registration number: CRD42021237649).


Subject(s)
Acute Kidney Injury , Anti-Inflammatory Agents, Non-Steroidal , Humans , Aged , Aged, 80 and over , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Acute Kidney Injury/chemically induced , Analgesics, Opioid/adverse effects , Postoperative Complications/chemically induced , Pain/drug therapy
2.
Rev Infirm ; 69(263): 40-42, 2020.
Article in French | MEDLINE | ID: mdl-32993906

ABSTRACT

Collectif Doloplus: twenty-five years supporting the fight against pain in the elderly. Speech and communication disorders among the elderly can be an obstacle in the detection and evaluation of pain. In these conditions, the Doloplus and Algoplus (heteroassessment) behavioural scales should be used. This article provides an overview of the guidelines for using these two scales and the role each has in daily practice. It also shows the impact a high-quality evaluative approach can have on the care provided.


Subject(s)
Pain Management , Pain , Aged , Humans , Pain Measurement , Practice Guidelines as Topic
4.
Trials ; 21(1): 138, 2020 Feb 04.
Article in English | MEDLINE | ID: mdl-32019598

ABSTRACT

BACKGROUND: Among palliative care (PC) patients who are administered paracetamol, the subcutaneous (SC) route is often an alternative to the intravenous (IV) route. Yet pharmacological and clinical data on whether these are equivalent pharmacokinetically are lacking. Many French palliative teams are now empirically using paracetamol by the SC route, but there are no data to support this practice. This trial aims to compare the pharmacokinetic (PK) parameters of paracetomol between the IV and SC routes in PC patients. METHODS/DESIGN: This is a randomized, open, crossover study in two PC centers. The primary endpoints are AUC0-t, AUC0-∞, Cmax, Vd, and t1/2. All adverse events will be reported for a safety analysis. Twenty adult PC patients with an IV device having spontaneous pain not related to care, with a numeric pain rate scale > 3/10, or having a systematic prescription of paracetamol as the usual treatment will be included. All patients also have to meet all eligibility criteria. CONCLUSION: This is the first study comparing PK parameters for IV paracetamol versus SC paracetamol in PC patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03944044. Registered on 4 June 2019. Committee for the protection of persons (CPP) 18.09.05.58206 approval 4 October 2018. National Drug Safety Agency (ANSM; Agence Nationale de Sécurité Médicament) MEDAECNAT-2018-09-00009 approval 29 November 2018.


Subject(s)
Acetaminophen/administration & dosage , Acetaminophen/pharmacokinetics , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/pharmacokinetics , Multicenter Studies as Topic , Pain Management/methods , Pain/drug therapy , Palliative Care/methods , Randomized Controlled Trials as Topic , Adolescent , Adult , Aged , Aged, 80 and over , Cross-Over Studies , Female , France , Humans , Injections, Intravenous/adverse effects , Injections, Subcutaneous/adverse effects , Male , Middle Aged , Therapeutic Equivalency , Treatment Outcome , Young Adult
5.
Bull Cancer ; 105(11): 1074-1083, 2018 Nov.
Article in French | MEDLINE | ID: mdl-30327192

ABSTRACT

Pain, one of the most feared symptoms for patients with cancer, remains insufficiently alleviated and impairs quality of life. Therapeutic patient education (TPE) is a relevant approach to this problem while allowing patients to develop skills to better manage their pain. In the "Basse-Normandie" French region, the management of pain relies on two organized networks, thus allowing proximity and accessibility for all concerned. In this context, our team has begun a broad five-step research program that is part of a regional health policy: (1) training in TPE of 10 doctor/nurse pairs; (2) identification of educational expectations of patients and their relatives in the field of cancer pain; (3) design and optimization of a TPE program dedicated to cancer pain; (4) regional pilot study aiming to assess the feasibility, quality and transferability of the program; (5) evaluation of the TPE program by interventional comparative randomization at the national level. This article aims to present the program which originality and strengths are based on collaborative work between health stakeholders. Objectives, methodology and expected results of the research phase (stages 2, 4, 5) are notably developed. The main expected outcomes are to prove the effectiveness of the program in improving the knowledge and skills of patients in the field of pain cancer in order to promote their adherence to treatment and, consequently, to enable them to better manage it. The long-term objective is to disseminate the educational approach by modifying practices that provide a mutual benefit for caregivers and patients.


Subject(s)
Cancer Pain/therapy , Patient Education as Topic , Program Development , Caregivers/education , Humans , Patient Satisfaction , Pilot Projects , Program Evaluation
7.
Geriatr Psychol Neuropsychiatr Vieil ; 16(2): 133-144, 2018 Jun 01.
Article in English | MEDLINE | ID: mdl-29687782

ABSTRACT

The main objective of this study is to describe the current therapeutic strategy for pain in elderly patients, by general practitioners. In this prospective study, 149 patients aged 75 years and over, hospitalized in geriatric medicine at the University Hospital of Caen, were recruited between June and September 2015. All analgesic data was recorded from the patients' prescriptions and medical files. 66% of the patients had at least one analgesic. More than 96% of patients who took analgesics were treated with a step 1 analgesic (mainly paracetamol), and approximately 30% received a step 2 analgesic (69% tramadol). Only 8% received step 3 analgesics. The proportion of patients treated with an antiepileptic was higher in cases of neuropathic pain. Adjuvant drugs were prescribed 17.3% on doctor's orders. Pain was mainly of a mechanical nature, due to osteoarthritis. The results of the study exhibit a well-balanced therapeutic management of pain by general practitioners for ambulatory elderly patients in agreement with the guidelines.


Subject(s)
Analgesics/therapeutic use , Drug Prescriptions/statistics & numerical data , General Practitioners/statistics & numerical data , Geriatrics/statistics & numerical data , Age Factors , Aged , Aged, 80 and over , Drug Utilization , Female , France , Humans , Male , Medication Therapy Management , Prospective Studies
8.
Geriatr Psychol Neuropsychiatr Vieil ; 16(2): 121-132, 2018 Jun 01.
Article in English | MEDLINE | ID: mdl-29661745

ABSTRACT

The main objective is to analyze the evolution of analgesic treatment three to five months after a hospitalization in geriatric medicine for patients aged 75 and over, considering the influences of various factors and reasons of modifications. In this single institution and cohort study, patients were included from geriatric medicine at the University Hospital of Caen. Analgesic treatments were collected during hospitalization. Three months post-hospitalization, general practitioners were contacted regarding the evolution of the analgesic treatment. Patients included were hospitalized between June and September 2015. Three months after hospitalization, 75 patients had useful data. There were changes of treatment for 58.7 % of patients (n=44), most of whom had a reduction of treatment (n=23). The main cause for change was the occurrence of an intercurrent event, 34.1 % (n=15), in particular a new hospitalization (n=11), and pain improvement : 31.9 % (n=14). The presence of tramadol on discharge prescriptions was an influent factor of the treatment change three months post-hospitalization. After a hospitalization, general practitioners have an important role in the necessary adaptation of pain treatment in the patient's everyday life.


Subject(s)
Analgesics/therapeutic use , Drug Prescriptions/statistics & numerical data , Geriatrics/statistics & numerical data , Pain/drug therapy , Aged , Aged, 80 and over , Cohort Studies , Drug Utilization/statistics & numerical data , Female , France/epidemiology , Hospitalization , Humans , Male , Outpatients , Pain/epidemiology , Pain Management/statistics & numerical data , Treatment Outcome
9.
J Cancer Educ ; 33(6): 1355-1361, 2018 12.
Article in English | MEDLINE | ID: mdl-28804809

ABSTRACT

In the field of cancer pain, therapeutic patient education (TPE) allows patients to develop skills to better manage their pain. In the Lower Normandy region of France, the management of pain is based on networking, thus allowing proximity and accessibility for all concerned. We have thus designed and initiated a broad five-stage research program that includes the following: (1) training for caregivers in TPE; (2) identifying the educational expectations of patients and their relatives with regard to cancer pain; (3) the design of a TPE program; (4) the evaluation of its quality; and (5) the evaluation of its effectiveness by comparative randomization. This article presents this approach and more particularly the research phases (stages 2, 4, 5) for which the objectives, the methodology, and the expected results are justified. Among the key points, particular attention is paid to the evaluation of the educational dimension that provides patients with self-efficacy to participate actively in the management of their pain, their perception of changes in relation to it and its impact. The choice of a specific assessment criterion (subscale 9 of the Brief Pain Inventory) and of the step-wedge design are thus argued. This approach, which is based on a partnership between health care professionals and researchers, aims to demonstrate the benefits provided by TPE to patients in order to enable them to better manage their pain on a daily basis.


Subject(s)
Biomedical Research , Cancer Pain/therapy , Caregivers/education , Health Personnel/education , Patient Education as Topic/methods , Program Development , France , Humans , Patient Education as Topic/organization & administration
10.
Rev Prat ; 68(1): 61-62, 2018 Jan.
Article in French | MEDLINE | ID: mdl-30840391
11.
J Immunother ; 40(4): 129-131, 2017 May.
Article in English | MEDLINE | ID: mdl-28267050

ABSTRACT

The anti-programmed cell-death-1 antibody, nivolumab, has been recently approved for the treatment of advanced non-small cell lung cancer. Although, today, immune-related adverse effects such as dermatologic, digestive, hepatic, and endocrine toxicities are well-known with immune checkpoint inhibitors, rheumatic diseases are less well described. Herein, we report the case of a patient without a history of arthritis who developed polymyalgia rheumatica after 13 cycles of nivolumab used for the treatment of advanced non-small cell lung cancer. Laboratory evidence of inflammatory syndrome, articular echography, and clinical presentation with classical symptoms and also distal manifestations were suggestive of this chronic inflammatory disorder. Because of a relevant pain, clinicians were forced to suspend immunotherapy. Nevertheless, due to glucocorticoid therapy, the patient's symptoms have decreased progressively. Moreover, nivolumab was reintroduced 8 weeks later, whereas prednisone (10 mg) was continued, without any recurrence symptoms. To conclude, our case suggests that polymyalgia rheumatica might be a very disabling anti-programmed cell-death-1 immune-related adverse effect.

SELECTION OF CITATIONS
SEARCH DETAIL
...